TC BioPharm (Holdings) PLC, a foreign private issuer, filed a Form 6-K with the SEC for July 2024, indicating the indefinite adjournment of its first 2024 Annual General Meeting (AGM) due to insufficient quorum as per Nasdaq rules. The company, having satisfied UK quorum requirements, announced a second AGM scheduled for July 24, 2024, at its UK office. Shareholders of record as of July 22, 2024, are entitled to vote, with ADS holders voting by proxy before July 19, 2024. The agenda includes receiving the annual report, approving directors' remuneration, ratifying the appointment of Marcum LLP as the U.S. auditor, re-appointing Ecovis as the UK auditor, and authorizing the Audit Committee to determine auditor remuneration.

TC BioPharm (Holdings) PLC, a foreign private issuer, filed a Form 6-K with the SEC for July 2024, indicating the indefinite adjournment of its first 2024 Annual General Meeting (AGM) due to insufficient quorum as per Nasdaq rules. The company, having satisfied UK quorum requirements, announced a second AGM scheduled for July 24, 2024, at its UK office. Shareholders of record as of July 22, 2024, are entitled to vote, with ADS holders voting by proxy before July 19, 2024. The agenda includes receiving the annual report, approving directors' remuneration, ratifying the appointment of Marcum LLP as the U.S. auditor, re-appointing Ecovis as the UK auditor, and authorizing the Audit Committee to determine auditor remuneration.